Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non-Invasive Skin Biopsy Test Allows Clinicians to Look inside Nerves for Diagnosing Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 24 Mar 2023

The diagnosis of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy can pose significant challenges for clinicians. More...

According to scientific studies, these disorders are misdiagnosed over 30% of the time, particularly during the early stages of presentation. Over the years, researchers have searched for biomarkers in the blood and spinal fluid and employed advanced radiographic methods to image neuron changes in the brain. However, these tests have not been sufficiently sensitive or specific, often failing to detect individuals with the diseases or indicating disease consistency in those who do not have them.

CND Life Sciences (Phoenix, AZ, USA) has developed the first-ever test in the market that can examine the nerves inside the human body and detect the protein accumulation in individuals with synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. These diseases are characterized by the accumulation of a misfolded protein called alpha-synuclein in the nervous system, which is unique to individuals with synucleinopathies.

The Syn-One Test is a minimally invasive skin biopsy (a punch biopsy with no stitches required) that provides physicians with visual evidence of these proteins accumulating within a patient’s nerves. Skin punch biopsy is an effective, reliable, non-invasive test for detecting such proteins, and can help find a cure for these neurodegenerative diseases. The reliability and effectiveness of this minimally invasive test have gained the attention of hundreds of clinicians across the US who are now using it as a diagnostic aid for the early detection of these synucleinopathies.

"Syn-One is changing the way clinicians diagnose many of these complex neurodegenerative diseases, and in parallel, biopharmaceutical companies are realizing how important it is to use Syn-One as a biomarker for clinical trials targeting alpha-synuclein," said Todd Levine, MD, CND's Chief Medical Officer and Co-Founder.

Related Links:
CND Life Sciences 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.